Alzheimer's disease drug pipeline

Upcoming readouts & recent results

• By end-2026AnticipatedJNJ-2056 (ACI-35.030)Topline dataNCT06544616

  Phase 2b ReTain (NCT06544616): primary completion estimated 22 Dec 2026 (ClinicalTrials.gov); timing may shift given the Feb-2026 recruitment pause. ↗

• 2H 2026AnticipatedMK-1167Topline dataNCT06721156

  Phase 2 topline efficacy/safety of MK-1167 (vs placebo) on cognition in mild-to-moderate Alzheimer's disease dementia (MK-1167-008) ↗

• 2H 2027AnticipatedITI-1284 (deulumateperone)Topline dataNCT06540833

  Anticipated Phase 2 topline for ITI-1284 in psychosis associated with Alzheimer's disease (NCT06540833); primary completion targeted September 2027. ↗

• January 2029AnticipatedLHP588Registry resultsNCT06847321

  ClinicalTrials.gov estimated primary completion of the Phase 2 SPRING trial (NCT06847321) of LHP588 25 mg and 50 mg vs placebo in P. gingivalis-positive mild-to-moderate Alzheimer's disease: January 2029 (estimated study completion 2029-03-15). ↗

• 2029AnticipatedMK-2214Topline dataNCT07033494

  Anticipated Phase 2 readout in early Alzheimer's disease: change in tau PET SUVr (primary), per estimated primary completion April 2029. ↗

• 2026-03-21ReportedPosdinemabFull resultsmissedNCT04619420

  AuTonomy Phase 2b full results (AD/PD 2026): posdinemab missed the primary iADRS endpoint - no significant difference for either dose vs placebo at week 104; key secondaries also negative; tau-PET suggested slowed neurofibrillary-tangle accumulation. Program discontinued. ↗

• 2026-02-17ReportedJNJ-2056 (ACI-35.030)Interim analysispendingNCT06544616

  Phase 2b ReTain (NCT06544616): Janssen temporarily paused recruitment (17 Feb 2026); voluntary, not safety-related, pre-specified interim immunogenicity threshold met; dosing/follow-up of enrolled participants continues. ↗

• 2025-12-01ReportedMK-2214Full resultsmetNCT05466422

  Phase 1 first-in-human MK-2214 data at CTAD 2025: favorable safety/PK and CSF pS413 tau reductions consistent with near-saturating target engagement; FDA Fast Track granted. ↗

• 2025-12-01ReportedMK-1167Interim analysis

  Phase 1 healthy-volunteer biomarker data: single doses of MK-1167 modulate prefrontal-cortex glutamate metabolism measured by 13C-magnetic resonance spectroscopy (presented at CTAD 2025) ↗

See the full catalyst calendar →

Compounds in development (7)

Also in development for subtypes of Alzheimer's disease

• RemlifanserinPhase 3ACADIA Pharmaceuticals Inc.for Alzheimer's disease psychosis
• ML-007C-MAPhase 2MapLight Therapeutics, Inc.for Alzheimer's disease psychosis
• AXS-05 (dextromethorphan-bupropion)ApprovedAxsome Therapeutics, Inc.for Agitation in Alzheimer's disease
• Dexmedetomidine sublingual film (BXCL501)Phase 3BioXcel Therapeutics, Inc.for Agitation in Alzheimer's disease
• ITI-1284 (deulumateperone)Phase 2Johnson & Johnsonfor Agitation in Alzheimer's disease
• NMRA-511Phase 1Neumora Therapeutics, Inc.for Agitation in Alzheimer's disease

Trials recruiting now (151)

151 drug-interventional alzheimer's disease trials recruiting now, of 1,537 registered interventional trials. Browse all on ClinicalTrials.gov →

• Phase 4Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

  Donanemab, Placebo

  Michael Rafii, MD, PhDn=60Started Aug 2026NCT06911944
• Phase 4Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment

  Ginkgo Biloba Extract 240 mg, Placebo

  Hanyang Universityn=120Started Jun 2026NCT07579689
• Phase 4A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

  Zunveyl®

  Alpha Cognition, Incn=150United States · 1 siteStarted Jun 2026NCT07633470
• Phase 4Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

  Lecanemab 10 mg/kg, Conventional anti-dementia treatment group

  First Affiliated Hospital of Wenzhou Medical Universityn=200China · 1 siteStarted Jan 2026NCT07604896
• Phase 4Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

  cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)

  University Hospital, Bordeauxn=1,205France · 31 sitesStarted Jun 2024NCT03454646
• Phase 4Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

  Daridorexant 50 mg, Placebo

  University Hospital, Montpelliern=62France · 1 siteStarted Mar 2024NCT05924425
• Phase 4An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

  GV-971, Placebo

  Green Valley (Shanghai) Pharmaceuticals Co., Ltd.n=1,312China · 50 sitesStarted Aug 2023NCT05908695
• Phase 4Aβ Dynamics in LLMD

  Escitalopram Oxalate, Placebo

  NYU Langone Healthn=60United States · 2 sitesStarted Feb 2022NCT05004987
• Phase 4Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

  Gabapentin Enacarbil, Placebo Oral Tablet

  University of Texas at Austinn=156United States · 1 siteStarted Jul 2017NCT03082755
• Phase 3GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

  GV1001 Placebo, GV1001 1.12mg

  Samsung Pharmaceutical Co., Ltd.n=750Started Jul 2027NCT05303701
• Phase 3Alzheimer's Disease THErapy With NEuroaid II

  MLC 901, Placebo

  Moleac Pte Ltd.n=350Singapore · 1 siteStarted Aug 2026NCT07191028
• Phase 3Masitinib in Patients With Mild Alzheimer's Disease

  Placebo, Masitinib (4.5), Standard of care

  AB Sciencen=600France, Spain · 9 sitesStarted Jun 2026NCT05564169

Showing the 12 most advanced of 151 recruiting drug trials · see all on ClinicalTrials.gov →